Skip to content

Health— page 6

health

Congo’s Ebola deaths top 1,000 as violence and shortages hamper medics

July 23 (Reuters) – Ebola has now killed more than 1,000 people in the Democratic Republic of Congo, official figures show, as medics struggle to contain an outbreak amid militant violence, attacks on clinics and widespread shortages. The number of confirmed Ebola cases has increased to 2,536, Congo

· SRN Health
Congo’s Ebola deaths top 1,000 as violence and shortages hamper medics
health

Indonesia’s tobacco industry protests plan to toughen rules

JAKARTA, July 23 (Reuters) – Indonesia’s tobacco groups pushed back on Thursday against government plans for tougher regulations on cigarette making and marketing, saying the $40-billion industry will be harmed by proposed limits on nicotine and tar content, among others. The regulations set to be i

· SRN Health
Indonesia’s tobacco industry protests plan to toughen rules
health

India’s Cipla posts another profit decline, names insider Dinesh Jain CFO

July 23 (Reuters) – India’s Cipla posted a bigger-than-expected fall in first-quarter profit on Thursday, logging its third straight quarterly decline as muted sales of a generic cancer drug and U.S. supply disruptions related to tumor treatment lanreotide weighed on results. The drugmaker also appo

· SRN Health
health

AI shortens drug discovery to around 1 year in China, Insilico CEO says

By Laurie Chen SHANGHAI, July 23 (Reuters) – Hong Kong-listed Insilico Medicine has cut drug development timelines to about one year by combining AI with its China research ecosystem, its CEO said, giving it an edge over traditional Western pharmaceutical giants. Its strategy highlights how China’s

· SRN Health
health

Argenx’s Vyvgart sales jump in second quarter, shares climb

By Lucie Barbier July 23 (Reuters) – Belgian-Dutch immunology company argenx said on Thursday that global sales of its lead drug Vyvgart jumped in the second quarter of 2026 from a year earlier, sending its shares higher. Vyvgart sales came in at $1.516 billion in the second quarter, up 60% from $94

· SRN Health
health

Sartorius beats half-year earnings expectations aided by tariff refunds

July 23 (Reuters) – German biopharma supplier Sartorius reported half-year earnings slightly above market expectations on Thursday, citing stable recurring business and the effect of U.S. tariff refunds. The company reported an underlying earnings margin before interest, taxes, depreciation and amor

· SRN Health
health

Indian drugmaker Dr Reddy’s slips on margin, semaglutide supply woes

July 23 (Reuters) – Shares of Dr Reddy’s Laboratories declined 4.4% on Thursday after brokerages cut their earnings forecasts for the Indian drugmaker after weaker-than-expected quarterly results and semaglutide supply disruptions. The stock was trading at 1,130 rupees, its lowest in over one year,

· SRN Health
Indian drugmaker Dr Reddy’s slips on margin, semaglutide supply woes
health

Hair loss with GLP-1 drugs is rare, but real, studies find

By Nancy Lapid July 22 (Reuters) – The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest. At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37% hi

· SRN Health
Hair loss with GLP-1 drugs is rare, but real, studies find
health

Molina’s profit forecast lift overshadowed by Obamacare weakness

By Padmanabhan Ananthan July 22 (Reuters) – Molina Healthcare raised its annual profit forecast on Wednesday after posting second-quarter profit and revenue that beat Wall Street estimates, helped by stronger-than-expected performance in its Medicaid and Medicare businesses. The health insurer now e

· SRN Health
health

Pfizer’s prostate cancer drug combination gets US FDA priority review

July 22 (Reuters) – Pfizer said on Wednesday the U.S. Food and Drug Administration had granted priority review to its application seeking expanded approval for its prostate cancer treatment combination. The company had sought expanded approval to use a combination of two approved drugs — branded as

· SRN Health
Pfizer’s prostate cancer drug combination gets US FDA priority review
health

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

By Dietrich Knauth July 22 (Reuters) – A federal judge cast doubt on Wednesday on claims by approximately 69,000 people alleging that Johnson & Johnson’s baby powder and other talc products caused ovarian cancer, saying plaintiffs must provide more specific evidence or risk having their lawsuits dis

· SRN Health
US judge casts doubt on 69,000 cases alleging J&J talc caused cancer
health

US FDA says it is investigating another cyclosporiasis outbreak

July 22 (Reuters) – The U.S. FDA has said it is investigating a new outbreak of cyclosporiasis, with 72 cases tied to an as-yet-unidentified source. The agency’s announcement on Wednesday adds to the growing number of cyclosporiasis cases reported across the U.S. Midwest, including Michigan and four

· SRN Health
US FDA says it is investigating another cyclosporiasis outbreak
health

Generic drug sector seeks policy fixes after Trump tariff threat

July 22 (Reuters) – The generic drug market still faces structural and purchasing hurdles despite strong U.S. growth, an industry group noted on Wednesday, after President Donald Trump said imported generic medicines would face up to 200% tariffs after two years. “Our industry has grown significantl

· SRN Health
Generic drug sector seeks policy fixes after Trump tariff threat
health

GSK enters lung cancer drug market with early FDA nod for Jideytro

By Padmanabhan Ananthan and Bhanvi Satija July 22 (Reuters) – GSK said on Wednesday the U.S. FDA approved its drug to treat a form of lung cancer, nearly two months after the British drugmaker acquired the treatment as part of a historic $10.6 billion deal. The approval, which marks GSK’s entry into

· SRN Health
GSK enters lung cancer drug market with early FDA nod for Jideytro
health

FDA panel to review popular peptides amid persistent consumer appetite

By Sneha S K and Sriparna Roy July 22 (Reuters) – U.S. FDA advisers this week will weigh whether seven popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry participants say consumer demand is likely to remain strong. The review comes as

· SRN Health
FDA panel to review popular peptides amid persistent consumer appetite
health

Philip Morris to lift Zyn investment, cigarette demand drives earnings beat

By Neil J Kanatt and Emma Rumney July 22 (Reuters) – Philip Morris International said it would increase investment in its Zyn nicotine pouches as competition intensifies in the fast-growing category, after higher cigarette demand helped drive a quarterly results beat on Wednesday. Its shares rose ab

· SRN Health
Philip Morris to lift Zyn investment, cigarette demand drives earnings beat
health

J&J enters US robotic surgery market after device gets marketing authorization

By Puyaan Singh July 22 (Reuters) – Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, as the healthcare conglomerate enters the soft-tissue robotic surgery market. The decision marks a key step for J&J’s medt

· SRN Health
J&J enters US robotic surgery market after device gets marketing authorization
health

Congo’s Ebola outbreak has killed over 1,000 people

BUNIA, Congo (AP) — More than 1,000 people have died in the Ebola outbreak in Congo, according to Africa’s top health body, a grim toll in the fastest Ebola outbreak in history, as conflict, community resistance and an uneven response fuel its spread. Speaking at a health summit in Ghana on Wednesda

· SRN Health
Congo’s Ebola outbreak has killed over 1,000 people
health

India’s Dr Reddy’s posts quarterly profit slump on semaglutide inventory costs

HYDERABAD, July 22 (Reuters) – Indian drugmaker Dr Reddy’s reported a smaller-than-expected quarterly profit on Wednesday, weighed by inventory and related costs associated with disruptions to semaglutide supply, the company said. Consolidated net profit tanked 68.7% to 4.44 billion rupees ($45.98 m

· SRN Health
health

Repligen beefs up cell therapy business with $1.5 billion deal for BioLife

By Sahil Pandey July 22 (Reuters) – Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider’s presence in the fast-growing cell therapy market. Shares of BioLife rose about 6% and those of Repli

· SRN Health
health

Congo says nearly 1,000 die of Ebola, confirmed cases rise to 2,473

DAKAR, July 22 (Reuters) – The number of confirmed Ebola cases in the Democratic Republic of Congo has increased to 2,473, including 999 deaths, government data showed on Wednesday. The country’s public health institute said in its latest report that 50 new cases were detected on Monday in the easte

· SRN Health
Congo says nearly 1,000 die of Ebola, confirmed cases rise to 2,473
health

Lonza lifts margin target, repeats latter half of 2026 to be slower

By Bartosz Dabrowski and Kira Britten July 22 (Reuters) – Lonza, the world’s largest contract drug manufacturer, raised its margin goal but stuck with the earlier revenue target on Wednesday, as it reiterated that growth and profitability would moderate in the second half of 2026. The Swiss firm now

· SRN Health
Lonza lifts margin target, repeats latter half of 2026 to be slower